After Hours
$
47.03
Change
+0.0100 +0.02%
Volume
Volume 888
Dec 4, 2023, 4:08 p.m.
Quotes are delayed by 20 min
Today's close
$ 46.72
$ 47.02
Change
+0.30 +0.64%
Day low
Day high
$46.60
$47.15

52 week low
52 week high
$42.63
$57.82

Market cap
$116.79B
Average volume
2.25M
P/E ratio
13.18
Rev. per Employee
$494,994
EPS
3.57
Dividend
N/A
Div yield
2.92%
Ex dividend date
5/26/22
MarketWatch News on SNY
-
A Golden Age of Vaccines Is Here. What It Means for You.
- Neal Templin
-
Teva shares climb as third-quarter sales top estimates
- Eleanor Laise
-
Pharma Stocks Are Bleeding. 2 Look Like Bargains.
- Josh Nathan-Kazis
-
Moderna Reports Big Loss in Post-Pandemic Reset
- Josh Nathan-Kazis
-
Novo Nordisk Earnings Surge. It Can't Make Weight-Loss Drugs Fast Enough.
- Josh Nathan-Kazis
-
GSK Raises Guidance on Strong Sales of Arexvy Vaccine
- Josh Nathan-Kazis
-
Drug Stocks Keep Tanking on Earnings. Brace for More.
- Josh Nathan-Kazis
-
MeiraGTx shares jump as Sanofi invests in gene therapy
- Eleanor Laise
-
Sanofi to Spin Out Consumer Health Division
- Josh Nathan-Kazis
-
Companies Push Forward With RSV Vaccine Amid Shortages
- Josh Nathan-Kazis
-
- Janet H. Cho
-
Big Tech Stocks, Boeing Earnings, GDP, and More
- Nicholas Jasinski
-
Moderna Says Flu-Covid Vaccine Succeeds in Early-Stage Trial
- Josh Nathan-Kazis
-
Teva partnership with Sanofi ‘will pay dividends,’ analyst says
- Eleanor Laise
-
Pfizer maternal RSV vaccine recommended by CDC
- Eleanor Laise
-
Pfizer maternal RSV vaccine recommended by CDC advisors
- Eleanor Laise
- Loading more headlines...
Analyst Ratings
-
Analysts See a 9.5% Upside for SNY Stock over the Next Year
- MarketRealist.com
-
Analysts’ Recommendations for Valeant in June
- MarketRealist.com
Other News on SNY
-
Why Covid Lockdowns and Mask Mandates Made Children Sicker
- The Wall Street Journal Interactive Edition
-
Bayer Mulls Possible Split of Crops or Consumer Health
- The Wall Street Journal Interactive Edition
-
When to Get Your Covid-19, Flu and RSV Shots This Fall
- The Wall Street Journal Interactive Edition
-
Why Drug Companies Don’t Want to Sell Allergy Medicines and Bandages Anymore
- The Wall Street Journal Interactive Edition
-
New RSV Drug Has Limited Supply, CDC Says
- The Wall Street Journal Interactive Edition
-
This $5 Billion Biotech Home Run Took Less Than a Year
- The Wall Street Journal Interactive Edition
-
Pro Take: Making Medicines Greener
- The Wall Street Journal Interactive Edition
-
Sanofi Faces Third-Quarter Forex Hit
- The Wall Street Journal Interactive Edition
-
J&J Revamps Drug Research, Plots Medical Device Deals
- The Wall Street Journal Interactive Edition
-
FDA Approves RSV Vaccine to Pass Protection From Mother to Child
- The Wall Street Journal Interactive Edition
-
Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
- The Wall Street Journal Interactive Edition
-
Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet
- The Wall Street Journal Interactive Edition
-
FDA Approves First RSV Drug to Protect All Infants
- The Wall Street Journal Interactive Edition
-
Sanofi Wins Supreme Court Patent Dispute With Amgen
- The Wall Street Journal Interactive Edition
-
J&J Prices Consumer Unit IPO at $22 a Share
- The Wall Street Journal Interactive Edition
-
FDA Approves GSK’s RSV Vaccine for Older Adults
- The Wall Street Journal Interactive Edition
-
J&J Consumer-Health Unit’s Listing to Test IPO Market
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
Amgen Seeks to Monopolize Nature
- The Wall Street Journal Interactive Edition
-
Regeneron, Sanofi Look for Billions From COPD Drug
- The Wall Street Journal Interactive Edition
- Loading more headlines...
Press Releases on SNY
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com